Key result
Genotype-guided warfarin in AF is linked to ~12% fewer elevated D-dimer cases versus traditional dosing.
Why the study?
The study was conducted to evaluate indicators of induced platelet aggregation and D-dimer levels in patients with AF depending on the method of warfarin dosing.
Does genotype-guided warfarin dosing reduce platelet aggregation and D-dimer levels in patients with atrial fibrillation?
Observational (n=110)
Does genotype-guided warfarin dosing reduce platelet aggregation and D-dimer levels in patients with atrial fibrillation?
Genotype-guided warfarin dosing in patients with atrial fibrillation significantly reduces ADP-induced platelet aggregation and the frequency of elevated D-dimer levels compared to traditional empirical dosing, suggesting a potentially lower risk of thrombotic events.
Answers are grounded in this paper and cite their sources.
Supports genotype-guided warfarin dosing to lower thrombotic risk in AF; extends RCT evidence for pharmacogenomic anticoagulation.
The aim. To evaluate indicators of induced platelet aggregation and D-dimer level in patients with atrial fibrillation (AF) depending on the method of warfarin (WF) dosing. Materials and methods. The study involved 110 patients with AF (mean age 68.72 ± 0.79; men – 57, women – 53). Patients with AF were divided into two groups: the main group – 50 patients with AF and genotype-guided dosing method, the control group – 60 patients with AF and traditional dosing method. CYP2C9, CYP4F2, VKORC1 genetic polymorphisms were determined using multiplex real time polymerase chain reaction, D-dimer concentration – by the method of solid-phase enzyme immunoassay; ADP- and epinephrine-induced aggregation indicators – by the method of G. Born. Results. The percentage (by 24 %), time (by 3 min 6 s) and rate in 30 s (by 19.5 %/min) of ADP-induced platelet aggregation were significantly lower in patients with AF and genotype-guided WF dosing method. D-dimer concentration in patients of the main and control groups did not differ significantly. However, significantly fewer patients with elevated D-dimer values were registered in the group with genotype-guided WF dosing method compared to the group with traditional dosing method: 0 (0.00 %) vs. 7 (11.67 %) at 500 ng FEU/ml cut-off (χ2 = 4.43, P < 0.05), 1 (2.00 %) vs. 9 (15.00 %) at 390 ng FEU/ml cut-off (χ2 = 4.16, P < 0.05), 0 (0.00 %) vs. 7 (11.67 %) at age-adjusted cut-off (χ2 = 4.43, P < 0.05). Conclusions. The obtained results may indicate a potentially lower risk of thrombotic events in patients with AF and genotype-guided WF dosing method compared to the group with traditional dosing method, which confirms the benefit of the widespread use of the pharmacogenetic testing in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kolesnyk et al. (2022) conducted an observational in atrial fibrillation (n=110). Genotype-guided warfarin dosing vs. Traditional warfarin dosing was evaluated on Elevated D-dimer values at 500 ng FEU/ml cut-off (p=< 0.05). Genotype-guided warfarin dosing in atrial fibrillation patients resulted in fewer patients with elevated D-dimer values compared to traditional dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: